

## Harm, Cohort Study

Citation:

Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. *JAMA Neurol.* 2016; 73(4):410-416. doi:10.1001/jamaneurol.2015.4791

<b>How serious is the risk of bias?</b>	
<b>Aside from the exposure of interest, did the exposed and control groups start and finish with the same risk for the outcome?</b>	
Were the patients similar for prognostic factors that are known to be associated with the outcome (or did statistical adjustment level the playing field)?	
Were the circumstances and methods for detecting the outcome similar?	
Was the follow-up sufficiently complete?	
<b>What are the Results?</b>	
How strong is the association between exposure and outcome?	
How precise is the estimate of risk?	
<b>How can I apply the results to my patient care?</b>	
Were the study patients similar to patients in my practice?	
Was follow-up sufficiently long?	
Is the exposure similar to what might occur in my patient?	
What is the magnitude of the risk?	
Are there any benefits that are known to be associated with the exposure?	

*Adapted from Duke and McMaster Evidence-based Practice Workshops and Users' Guide to the Medical Literature 3<sup>rd</sup> Ed.*